First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results
Year: 2016
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Martine Bagot, Pierluigi Porcu, Caroline Ram-Wolff, Michael Khodadoust, Maxime Battistella, Anne Marie-Cardine, Steve Mathieu, Maarten H. Vermeer, Sean Whittaker, Madeleine Duvic, Armand Bensussan, Carine Paturel, Cecile Bonnafous, Nicolas Thonnart, Agnes Widemann, Cecile Bonin, Helene Sicard, Christine Paiva, Korinna Pilz, Youn Kim
Institutions: Inserm, Hôpital Saint-Louis, HIPI - Immunologie humaine, physiopathologie et immunithérapie, The Ohio State University, Stanford Medicine, Stanford University, Leiden University Medical Center, King's College London, The University of Texas MD Anderson Cancer Center, Innate Pharma (France)
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2593445710